FRESENIUS MEDICAL CARE AG &
FRESENIUS MEDICAL CARE AG &/ DE0005785802 /
FME/D
|
11/30/2023 9:27:16 AM
|
Chg.
-0.13
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
37.15EUR
|
-0.35%
|
3,142
Turnover: 116,367.73 |
-Bid Size: - |
-Ask Size: - |
10.93 bill.EUR |
3.01% |
16.19 |
Business description
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. Around 2.8 M patients with this disease worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.
Management board & Supervisory board
| CEO |
| Helen Giza |
| Management board |
| Dr. Katarzyna Mazur-Hofsäß, Frank Maddux, MD, William Valle |
| Supervisory board |
| Dr. Dieter Schenk, Dr. Dorothea Wenzel, Gregory Sorensen, MD, Pascale Witz, Prof. Dr. Gregor Zünd, Rolf A. Classon |
Company data
| Name: |
Fresenius Medical Care AG & Co. KGaA |
| Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
| Phone: |
+49-6172-609-0 |
| Fax: |
+49-6172-609-2301 |
| E-mail: |
-
|
| Internet: |
www.fmc-ag.de |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12/31 |
| Free Float: |
44.95% |
| IPO date: |
10/2/1996 |
Investor relations
| Name: |
Dr. Dominic Heger |
| IR phone: |
+49 (0) 6172 609-2525 |
| IR Fax: |
+49 (0) 6172 609-2301 |
| IR e-mail: |
ir@fmc-ag.com
|
Company calendar
|
CW 12 | 3/22/2024
4th Quarter/Annual Report
|
|
CW 19 | 5/10/2024
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 5/16/2024
General Shareholder Meeting
|
|
CW 31 | 8/2/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 45 | 11/8/2024
Interim Report 3rd Quarter/9 Months
|